Lightnews — Scholar-powered news

David Sancho @sancholab.bsky.social · Jul 25

Gracias @caixaresearch.bsky.social por el sólido apoyo a nuestra investigación.
Este reporte es sobre las cDC1s en la generación de respuesta adaptativa en #atherosclerosis & #immunotherapy en el hilo www.ahajournals.org/doi/10.1161/...

También apoyo fundamental en: www.nature.com/articles/s41...

1 6

Reposted by David Sancho

Samir Giri @isamirgiri.bsky.social · Jul 23

This work identifies 'imidazole propionate' as a causal microbial metabolite that promotes atherosclerosis and shows that modulating its levels can potentially prevent cardiovascular disease risk, a promising therapeutic strategy.👇

David Sancho @sancholab.bsky.social · Jul 16

💥 A gut microbe metabolite that drives #atherosclerosis?
Yes—Imidazole propionate (ImP) triggers vascular inflammation without changing cholesterol.
🧪 We show the pathway—and how to block it.
nature.com/articles/s41... #OpenAccess at
@Nature
@CNIC_CARDIO
#CVD #immunosky #cardiosky #microbiomesky

Imidazole propionate is a driver and therapeutic target in atherosclerosis - Nature

Imidazole propionate produced by gut microbiota is associated with atherosclerosis in mouse models and in humans, and causes the development of atherosclerosis through activation of the imidazoline-1 ...

nature.com

2 7

David Sancho @sancholab.bsky.social · Jul 22

Thanks, Maya! we need to develop: 1) testing of ImP in blood samples; 2) treatments for people with high ImP to inhibit its sensing (as in the paper) or its production (by inhibiting bacterial UrdA enzyme). Ideally, along with other treatments (e.g. potential synergy with lipid-lowering treatments).

1 2

David Sancho @sancholab.bsky.social · Jul 20

Many thanks, Luis! 🫂 @lferreiramoita.bsky.social

David Sancho @sancholab.bsky.social · Jul 19

A gut microbiota metabolite linked to atherosclerosis could revolutionise diagnosis and treatment|ERC erc.europa.eu/news-events/...

A gut microbiota metabolite linked to atherosclerosis could revolutionise diagnosis and treatment

A new study led by the Spanish National Centre for Cardiovascular Research (CNIC) and funded by the European Reasearch Council (ERC) has identified imidazole propionate (ImP), a metabolite produced by...

erc.europa.eu

7 23

David Sancho @sancholab.bsky.social · Jul 17

Fantástico resumen por @manuelansede.bsky.social
🙏 @caixaresearch.bsky.social por financiar proyecto con 1 millón €
🙏 @ageinves.bsky.social por Severo Ochoa que inició el proyecto + 100K€ a nuestro lab
🙏 @erc.europa.eu ERC-CoG ERC-POC
#CNIC_CARDIO

Open acess: www.nature.com/articles/s41...

1 2 7

Reposted by David Sancho

Manuel Ansede @manuelansede.bsky.social · Jul 16

Revolución en la medicina: una molécula producida por bacterias del intestino causa la aterosclerosis, culpable de millones de muertes. El descubrimiento, del @sancholab.bsky.social, se acaba de publicar en la revista @nature.com 👇
elpais.com/salud-y-bien...

Revolución en la medicina: una molécula producida por bacterias del intestino causa la aterosclerosis, culpable de millones de muertes

El descubrimiento, gracias a un experimento con cientos de trabajadores del Banco Santander en Madrid, abre la puerta a nuevos tratamientos más allá de reducir el colesterol

elpais.com

1 26 64

David Sancho @sancholab.bsky.social · Jul 17

Thanks for the post, Ivan @lozanzi.bsky.social ! 🫂

1

Reposted by David Sancho

caixaresearch.bsky.social @caixaresearch.bsky.social · Jul 17

Esta investigación del CNIC revela que un metabolito de la microbiota intestinal favorece la aterosclerosis.

Descubre más de la mano de uno de los investigadores del equipo 👇🧬

David Sancho @sancholab.bsky.social · Jul 16

💥 A gut microbe metabolite that drives #atherosclerosis?
Yes—Imidazole propionate (ImP) triggers vascular inflammation without changing cholesterol.
🧪 We show the pathway—and how to block it.
nature.com/articles/s41... #OpenAccess at
@Nature
@CNIC_CARDIO
#CVD #immunosky #cardiosky #microbiomesky

Imidazole propionate is a driver and therapeutic target in atherosclerosis - Nature

Imidazole propionate produced by gut microbiota is associated with atherosclerosis in mouse models and in humans, and causes the development of atherosclerosis through activation of the imidazoline-1 ...

nature.com

3 4

David Sancho @sancholab.bsky.social · Jul 17

Gracias!!! 🤗🤗🤗

1

David Sancho @sancholab.bsky.social · Jul 17

Thanks, Toño!!! 🫂

1

David Sancho @sancholab.bsky.social · Jul 16

¡Gracias Carlos! 😊

David Sancho @sancholab.bsky.social · Jul 16

🙏🏻Main funding by @caixaresearch.bsky.social (1M€).
Additional support by @ageinves.bsky.social @erc.europa.eu ERC-2016-Consolidator Grant 725091; ERC-2023-PoC;
Other funders: @comunidadmadrid.extwitter.link @contracancerinv.bsky.social @worldwidecancer.bsky.social
DOI nature.com/articles/s41...

Imidazole propionate is a driver and therapeutic target in atherosclerosis - Nature

Imidazole propionate produced by gut microbiota is associated with atherosclerosis in mouse models and in humans, and causes the development of atherosclerosis through activation of the imidazoline-1 ...

nature.com

2 5

David Sancho @sancholab.bsky.social · Jul 16

📝 Study led by @annalaura-m.bsky.social & @iroblesv.bsky.social
🙏🏻collab #CNIC_CARDIO, #Borjaibanez1 starting this with me 7 years ago, Valentin Fuster, Fredrik Bäckhed on all ImP work, Göran Bergström IGT cohort, Kostas Stellos, Gabriel Nuñez Coral Barbas & many other col.

1 6

David Sancho @sancholab.bsky.social · Jul 16

🧪 ImP is a circulating biomarker of early and active #atherosclerosis, with diagnostic and therapeutic potential.
📉 Its effects are lipid-independent: ImP–I1R–mTOR axis in myeloid cells as a new therapeutic target for atherosclerosis. Synergy with lipid-lowering therapy?
#immunosky #cardiosky

1 2

David Sancho @sancholab.bsky.social · Jul 16

🧠 Mechanism: ImP acts through the imidazoline receptor I1R (Nischarin) in myeloid cells, activating mTOR and inducing TNF production.
🧬 Genetic or pharmacological blockade of I1R prevents #atherosclerosis development without lowering cholesterol.
#immunosky #cardiosky #microbiomesky

1 1

David Sancho @sancholab.bsky.social · Jul 16

🐭 In mice, oral ImP administration is sufficient to drive #atherosclerosis, without altering cholesterol or glucose.
🧪 It triggers #innate and #adaptive #immune activation and systemic inflammation.
#immunosky #cardiosky #microbiomesky

1 1

David Sancho @sancholab.bsky.social · Jul 16

In two independent human 🚶‍♀️🚶‍♂️cohorts (PESA @CNIC_CARDIO and IGT), plasma ImP levels were higher in people with subclinical #atherosclerosis, defined by multimodal advanced imaging (ultrasound, CT, PET-FDG). ImP linked to ACTIVE atherosclerosis in PESA.
#immunosky #cardiosky #microbiomesky

1

David Sancho @sancholab.bsky.social · Jul 16

🔬 Using #untargeted #metabolomics in #atherosclerosis-prone mice, we identified ImP as strongly associated with plaque formation, even in the absence of cholesterol changes.
🦠 ImP concentration depend on gut #microbiota composition.
#immunosky #cardiosky #microbiomesky

1 2

David Sancho @sancholab.bsky.social · Jul 16

💥 A gut microbe metabolite that drives #atherosclerosis?
Yes—Imidazole propionate (ImP) triggers vascular inflammation without changing cholesterol.
🧪 We show the pathway—and how to block it.
nature.com/articles/s41... #OpenAccess at
@Nature
@CNIC_CARDIO
#CVD #immunosky #cardiosky #microbiomesky

Imidazole propionate is a driver and therapeutic target in atherosclerosis - Nature

Imidazole propionate produced by gut microbiota is associated with atherosclerosis in mouse models and in humans, and causes the development of atherosclerosis through activation of the imidazoline-1 ...

nature.com

4 17 43

Reposted by David Sancho

Annalaura Mastrangelo @annalaura-m.bsky.social · Jul 16

Thank you to my co-author @iroblesv.bsky.social and
@sancholab.bsky.social for believing in this project and to all the researchers who contributed to this work!!

2 2

David Sancho @sancholab.bsky.social · Jul 16

Thanks, Christian! many years of team effort! 🫂

2

David Sancho @sancholab.bsky.social · Jul 1

Congrats @iannaconelab.bsky.social & team on a wonderful work @natimmunol.nature.com on the immune regulation in the liver: CD4+ T cells license Kupffer cells to rescue CD8+ T cells through IL12 & mainly IL27. Highly relevant for liver immunotherapy!!!
👏🏻👏🏻👏🏻👏🏻👏🏻
#immunosky
👇🏻👇🏻👇🏻

Iannacone Lab @iannaconelab.bsky.social · Jun 30

1/ 🚨 Hot off the press in Nature Immunology: CD4⁺ T cells can license Kupffer cells to rescue dysfunctional CD8⁺ T cells in the liver. Hepatitis B virus (HBV) infection is just the proving ground—this is a paradigm shift in tissue immunity. www.nature.com/articles/s41... 🧵(1/11)

6

David Sancho @sancholab.bsky.social · Jun 22

📝 Study led by Miguel Galán #CNIC_CARDIO
🙏🏻collaborators @cicbiomagune.bsky.social, @ciml.bsky.social, @washumedicine.bsky.social
🙏🏻#Fundación La Caixa @ageinves.bsky.social @comunidadmadrid.bsky.social @contracancerinv.bsky.social @worldwidecancer.bsky.social
#immunotherapy #immunosky #cardiosky

2

David Sancho @sancholab.bsky.social · Jun 22

🧩Conclusions:
✔️ cDC1s promote atherosclerosis via STING-driven IL-12 boost of Th1 & CD8+ T cell immunity
✔️ Targeted immunosuppression of cDC1s reduces inflammation and plaques
🧠 Novel precision strategy to tackle atherosclerosis beyond lipid control
#CardioImmunology #immunosky #cardiosky

1